SAN DIEGO — The recent withdrawal of Pfizer’s sickle cell drug Oxybryta has sparked outrage among sickle cell experts and patients alike. During a panel discussion at STAT@ASH, held in conjunction with the American Society of Hematology’s annual meeting, experts criticized Pfizer for what they deemed a “tone deaf” decision.
Patients were left despondent by the sudden removal of Oxybryta from the market in September, as there were no clear warning signs of safety concerns prior to the announcement. The panelists emphasized the importance of closer collaboration between pharmaceutical companies, specialists, and sickle cell centers of excellence to ensure the right patients receive the appropriate treatments.
Julie Kanter, a prominent sickle cell expert at the University of Alabama at Birmingham, highlighted the profit-driven nature of Oxybryta’s rollout, noting that the drug was “given out like water” without a comprehensive understanding of the diverse needs of the sickle cell patient population. Originally owned by biotech company Global Blood Therapeutics, Pfizer later acquired the drug, leading to further complications in its distribution.
The panelists called for greater transparency and accountability in the pharmaceutical industry, urging companies to prioritize patient safety and well-being over financial gain. The sudden withdrawal of Oxybryta serves as a stark reminder of the challenges faced by individuals living with sickle cell disease and the importance of ensuring access to safe and effective treatments.
As the sickle cell community grapples with the aftermath of Pfizer’s decision, it is crucial for stakeholders to learn from this experience and work together to improve the care and support available to those affected by this debilitating condition. Only through collaboration and a patient-centered approach can we hope to address the complex needs of individuals living with sickle cell disease.
